Abstract: The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.

Abstract: Compounds of Formula (I) have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful in the treatment of diseases of man where subnormal levels of this neurochemical are found, such as in Alzheimer's disease, and other conditions involving learning and cognition.

Abstract: Novel crystal forms of the fluoroquinolone, [S-(R*,S*)]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylam ino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid are disclosed. The forms are characterized by one methanol solvate form, and three anhydrous polymorphic forms, of which, Form III exhibits greatest stability and decreased hygroscopicity.

Abstract: The invention relates to novel compounds of the formula I in which the general symbols are as defined in claim 1, as stabilizers for organic materials against oxidative, thermal or light-induced degradation.

Abstract: This invention relates to peptide derivatives, pharmaceutical formulations containing those compound and methods of their use as thrombin inhibitors.

Abstract: The present invention provides peptide aldehydes having an azetidinyl, prolyl or pipecolyl group as part of the peptide backbone and an arginine mimic group such as an amidinopiperidine or amidinophenyl tail. These compounds are potent and specific inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis are also described.

Abstract: The subject invention provides for novel synergistic compositions useful for inactivating viruses or inducing apoptosis in tumor cells and for treating cancer or retroviral infections. Generally, the compositions comprise one or a plurality of ligands that oxidatively attack a zinc finger of pADPRT in combination with one or a plurality of agents selected from the group consisting of: agents that decrease cellular levels of glutathione and ligands that non-covalently bind to the nicotinamide site of pADPRT but do not effect zinc ejection from a zinc finger of pADPRT.

Abstract: A process for preparing glyphosate and other secondary amines of related structure in which a precursor primary amine such as aminomethylphosphonic acid is condensed with glyoxylic acid, or a related aldehyde compound, and the condensation product reduced without isolation to produce the desired product.

Abstract: Use of a polysaccharide selected from the group consisting of sulfated acid mucopolysaccharides and sulfated dextrans, and physiologically acceptable salts thereof for prophylaxis or treatment of inflammations, particularly an adult respiratory distress syndrome (ARDS), ischemic heart diseases, ischemic cerebral diseases, chronic articular rheumatism, atopic dermatitis, and infiltration after organ implantation.

Abstract: Pharmaceutical compositions comprising hyaluronic acid, non-steroidal inflammatory drugs, and organic salts of divalent metals, and methods of using these compositions for the inhibition of inflammation and adhesion formation are described.

Abstract: Heterogeneous vapor phase oxidation and other reactions are carried out at the surface of a solid catalyst, with both gaseous reactants and the solid catalyst being dispersed in a recirculating liquid solvent. Reaction and product absorption are combined into a single processing step, with enhanced catalyst performance, and product selectivity and product yields, enhanced mass and heat transfer characteristics and reduced risk of forming explosive mixtures in the course of a particular reaction.

Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

Abstract: The present invention is directed to compounds of formula (I), and the pharmaceutically acceptable acid addition salts thereof, wherein R is selected from the group consisting of F,--CF.sub.3, --OCH.sub.3, --O(C.sub.1)alkyl substituted with 1 to 3 fluoro atoms. --O(C.sub.2) substituted with 1 to 5 fluoro atoms, and --O(C.sub.3)alkyl substituted with 1 to 7 fluoro atoms. The compounds of formula (I) are useful in the treatment of stroke, traumatic brain injury and central nervous system degenerative diseases.

Abstract: The novel optically active 1,1'-biphenanthryl-2,2'-diol is disclosed, which is obtained by preparing N((S)-1-phenylethyl)-1,1'-biphenanthryl-2,2'-diylthiophosphorylamide by using optically active phenylethylamine, recrystallizing the compound into an optically active compound, followed by reduction with a reducing agent. The diol compound according to the present invention is useful as a resolving reagent, a starting material of an optically active phosphine compound or a ligand in asymmetric synthesis, forming a complex with a transition metal or a rare earth element to provide a useful catalyst.

Abstract: A method and apparatus for treating a surface on a glass article with a fluid. The article is surrounded by a containment system for the treating fluid and the fluid is continuously agitated by an agitator.

Abstract: The present invention relates to the field of photochromic material, in particular of photochromic compounds and matrices suitable for use in optical memory systems, including three dimensional optical memory systems for computers, multimedia applications and the like. The photochromic compounds have the following formula: ##STR1## wherein the substituents are defined in the specification.

Abstract: The present invention relates to compound LK6-A represented by the formula: ##STR1## which has immunosuppressive activity, and pharmaceutically acceptable salts thereof.

Abstract: An alkanediol such as 1,3-propanediol is prepared in a process which involves reacting an alkylene oxide with carbon monoxide and hydrogen in an essentially non-water-miscible solvent in the presence of a non-phosphine-ligated cobalt catalyst and a lipophilic ruthenium promoter to produce an intermediate product mixture containing a hydroxyalkanal in an amount less than 15 wt %; extracting the hydroxyalkanal from the intermediate product mixture into an aqueous liquid at a temperature less than about 100.degree. C. and separating the aqueous phase containing hydroxyalkanal from the organic phase containing cobalt catalyst; hydrogenating the hydroxyalkanal in the aqueous phase to an alkanediol; and recovering the alkanediol.The process enables the production of an alkanediol such as 1,3-propanediol in high yields and selectivity without the use of a phosphine ligand-modified cobalt catalyst.

Abstract: The present invention provides a method for treating a lipid body-mediated condition, such as inflammation or cancer, in an vertebrate by administering to the vertebrate a sufficient amount of an agent which inhibits the formation of lipid bodies in cells involved in inflammation. The agent can inhibit lipid body formation by inhibiting any biological activity necessary for lipid body formation.Another embodiment of the present invention is a method or assay for assessing the ability of a compound to inhibit lipid body formation in cells in vitro. The method comprises the steps of priming the cells for lipid body formation, contacting the cells with the compound under study, and comparing lipid body numbers in the cells with lipid body numbers in primed cells not contacted with the compound of interest. This method can be automated, yielding an efficient high-throughput assay for the efficient and rapid screening of large numbers of potential anti-inflammatory drugs.

Abstract: The invention relates to pharmaceutical compositions for the treatment or prevention of lesions of gastrointestinal mucous membranes and having secretion inhibiting, cytoprotective activities. The compositions contain in a biologically effective quantity a triazole-group-substituted quinoline derivative of general formula (I)R.sup.1 stands for a 1-triazolyl-group in position 2 or 4 ora 3-triazolyl-thio ora 5-/C.sub.1-4 -alkyl/-3-triazolyl-thio-group,R.sup.2 stands for a hydrogen atom in position 3 or optionally in position 2, or for a C.sub.1-4 -alkyl-group,R.sup.3 stands for a hydrogen atom or for a C.sub.1-4 -alkyl-group,X stands for a hydrogen or halogen-atom or for a C.sub.1-4 -alkyl-group or its salts. The invention includes processes for the preparation of the above compositions, and methods for treatment of patients in need of such treatment by administering the substance or the composition. The prefered substance of formula (IV) is also subject of the invention.